CELLCEUTIX PROVIDES UPDATE TO SHAREHOLDERS (9/28/14)
My fellow Cellceutix shareholders,
As I do periodically, I’d like to take a moment to discuss some of our accomplishments over the past year and update everyone on the current position of our company ...
Read More »
KevetrinOur technology - Kevetrin™ targets both MDM2-p53 and Rb-E2F pathways in tumor suppression.
Read more »
PrurisolOur technology KM-133 acts through immune modulation and PRINS reduction
BrilacidinOur technology - Brilacidin is the first of a completely new class of antibiotics called defensin-mimetics
More News »
Sign Up to Receive Alerts on Cellceutix click here.
More information available at clinicaltrials.gov